Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk

Toussirot, Éric; Aubin, F.; Desmarets, Maxime; Wendling, Daniel; Augé, B.; Gillard, J.; Messica, O.; Guillot, Xavier; Laheurte, Caroline; Monnet, Élisabeth; Dumoulin, Gilles

doi:10.1093/rheumatology/keaa720

Cited by 19 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that patients with psoriasis are characterized by visceral fat accumulation, whereas the amount of fat in this region did not differ between PsA patients and controls. Furthermore, visceral adiposity in psoriasis correlated with CV risk measurements, such as SCORE (49).…”

Section: Fat Mass Distribution In Psoriatic Diseasementioning

confidence: 92%

Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis

et al. 2021

View full text Add to dashboard Cite

PsA is characterized by a high prevalence of cardiovascular (CV) comorbidities. Recognizing these comorbidities is critical due to their influence on the quality of life and the choice of therapy. Imaging techniques also play an important role in the evaluation of the CV risk in psoriatic disease, improving the prediction of CV events when combined with clinical scores as a predictive tool. Meta-analyses point to a significant reduction in the incidence of CV events associated with the suppression of inflammatory activity when using systemic therapies. Consequently, the mortality rate in PsA patients has fallen in the last 40 years and is now similar to that of the general population, including cardiovascular causes. Obesity is an especially relevant CV comorbidity in patients with psoriatic disease, most of whom are overweight/obese. Body mass index (BMI) is a risk factor for PsA and a causal relationship with psoriasis has been demonstrated by Mendelian randomized studies. The study of fat distribution shows that patients with psoriasis are characterized by visceral fat accumulation, which correlates with CV risk measurements. These findings suggest that approaches to the prevention and treatment of psoriatic disease might come from targeting adiposity levels, in addition to the immune pathways. Weight loss treatment with low energy diets in patients with PsA has been associated with significant improvements in disease activity. Novel strategies using a multimorbidity approach, focused more on patients outcomes, are necessary to better address comorbidities, improve clinical outcomes and the quality of life of patients with psoriatic disease.

show abstract

Section: Fat Mass Distribution In Psoriatic Diseasementioning

confidence: 92%

Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…After testing for normality using the Kolmogorov-Smirnov test, the Mann-Whitney U Test for nonparametric data for independent samples was used, which revealed significant events, which have characteristically been associated with elevated BMI [4].…”

Section: Resultsmentioning

confidence: 99%

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy

Ruiz‐Villaverde

Ruiz‐Carrascosa

2022

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Visceral adipose tissue (VAT) has a greater relationship with the genesis of the metabolic syndrome and the pathology associated with obesity. Methods: A cross-sectional study of patients with moderate-severe psoriasis in the Psoriasis Unit of the San Cecilio University Hospital in Granada in the period July 1, 2020 - December 31, 2020, was performed. All the patients (n = 110) were receiving biological therapy to control the disease. The variables measured included age, sex, time since diagnosis, weight, height, body mass index (BMI), visceral and total fat, and severity parameters. The visceral fat index was evaluated using a bioimpedance scale, considering a cut-off point for a healthy level < 12. Results: Our sample consisted of 110 patients with a mean age of 47.47 years, with a clear predominance of males (61.7% of patients). After testing for normality using the Kolmogorov-Smirnov test, the Mann-Whitney U test for nonparametric data for independent samples was used, which revealed significant differences between the number of previous treatments and visceral fat (U = -2.235, P = 0.025). No statistically significant differences were found when correlating total fat or visceral fat with BMI. Conclusions: The results presented lead us to consider if the levels of VAT could be a factor that contributes to some extent to therapeutic refractoriness. The determination of VAT using bioimpedance scales in patients with moderate-severe psoriasis is a valuable method to measure VAT.

show abstract

“…The following devices were used to derive body composition data for analysis in the 10 included BIA studies: BIA 101, Akern srl, Pontassieve, Florence, Italy [19]; single-frequency 50 kHz BIA 101 RJL, Akern Bioresearch, Florence [21, 22, 25, 32]; Bodystat 1500, Bodystat Ltd., Douglas, Isle of Man, UK [28], Tanita SC-330 Body Composition Analyzer, Tanita Corp., Tokyo, Japan [36], InBody 170, Biospace, South Korea [33]; Tanita TBF300, Tanita Corporation, Tokyo, Japan [34, 35].…”

Section: Resultsmentioning

confidence: 99%

“…The sample size was small (< 40) for a number of studies [26, 29, 31, 37]. Overall, four studies were regarded to be at high risk of bias [15, 18, 23, 26], two at medium risk of bias [26, 29] and 18 at low risk of bias [18, 20–23, 25, 28, 30, 31, 33–41] using the ROBINS-I tool.…”

Section: Resultsmentioning

confidence: 99%

Psoriatic disease and body composition: a systematic review of the literature

Blake

Gullick

Hutchinson

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Obesity is a leading comorbidity in psoriatic disease, including both psoriasis (Pso) and psoriatic arthritis (PsA), and is associated with adverse metabolic and cardiovascular (CV) outcomes. Anthropometric parameters, such as weight, body mass index (BMI) and waist-to-hip ratio, have been extensively reported in psoriatic disease. However, the associations of body composition and fat distribution with psoriasis have not been fully defined. Objectives. To identify whether patients with psoriatic disease, including psoriatic arthritis, have altered body composition compared with the general population, and to review existing modalities for the assessment of body composition. Methods. Electronic searches of the literature were conducted in PubMed, Medline (Ovid), Embase (Ovid), Cochrane Central Register and Google Scholar. Titles and abstracts were reviewed by two authors independently against a set of prespecified inclusion/exclusion criteria. Results. Twenty-five full text articles met the inclusion criteria and were included in the final narrative analysis. The studies were of heterogeneous design and used a range of objective measures to assess body composition, including simple anthropometric measures, bioimpedance analysis (BIA), dual energy X-ray absorptiometry (DXA) and computed tomography (CT). Few studies met all the quality assessment criteria. Conclusions. Patients with psoriatic disease reveal defined body composition changes that are independent of obesity and the customary metabolic syndrome, including higher overall body fat, visceral fat and sarcopenia. These findings emphasize that patients with psoriatic disease should be screened for abnormal adipose effects beyond their weight and body mass index (BMI). Our findings show that the last decade has seen an exciting expansion of research interest in the development and validation of new modalities for the assessment of body composition. There is no consensus on the optimal assessment method of body composition for this diverse group, hence there is a need for validation of existing modalities and standardization of assessment tools.

show abstract

Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk

Cited by 19 publications

References 49 publications

Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis

Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy

Psoriatic disease and body composition: a systematic review of the literature

Contact Info

Product

Resources

About